1. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model
- Author
-
Wu, Wanlong, Jordan, Suzana, Becker, Mike Oliver, Dobrota, Rucsandra, Maurer, Britta, Fretheim, Håvard, Ye, Shuang, Siegert, Elise, Allanore, Yannick, Hoffmann-Vold, Anna-Maria, Distler, Oliver, University of Zurich, and Distler, Oliver
- Subjects
2403 Immunology ,Rheumatology ,1300 General Biochemistry, Genetics and Molecular Biology ,2745 Rheumatology ,General Biochemistry ,Immunology ,10051 Rheumatology Clinic and Institute of Physical Medicine ,2723 Immunology and Allergy ,Immunology and Allergy ,610 Medicine & health ,Genetics and Molecular Biology ,General Biochemistry, Genetics and Molecular Biology - Abstract
ObjectivesTo identify the predictive clinical characteristics and establish a prediction model for the progression of mild interstitial lung disease (ILD) in patients with systemic sclerosis (SSc).MethodsPatients with SSc from two independent prospective cohorts were included in this observational study. All patients fulfilled the 2013 American College of Rheumatology/European League Against Rheumatism criteria, had mild ILD at baseline diagnosed by High-Resolution Computed Tomography (HRCT), available baseline and ≥1 annual follow-up pulmonary function tests and no concomitant pulmonary hypertension or airflow obstruction. ILD progression was defined as a relative decrease in forced vital capacity (FVC)%≥15%, or FVC%≥10% combined with diffusing capacity for carbon monoxide %≥15% at 1-year follow-up. Candidate predictors for multivariate logistic regression were selected by expert opinion based on clinical significance. A prediction model for ILD progression was established in the derivation cohort and validated in the multinational validation cohort.ResultsA total of 25/98 and 25/117 patients with SSc showed ILD progression in the derivation cohort and the validation cohort, respectively. Lower SpO2 after 6 min walk test (6MWT) and arthritis ever were identified as independent predictors for ILD progression in both cohorts. The optimal cut-off value of SpO 2 after 6MWT for predicting ILD progression was determined as 94% by receiver operating characteristic curve analysis. The derived SPAR model combining both predictors (SPO2 and ARthritis) increased the prediction rate from 25.5% to 91.7% with an area under the curve (95% CI) of 0.83 (0.73 to 0.93).ConclusionsThe evidence-based SPAR prediction model developed in our study might be helpful for the risk stratification of patients with mild SSc-ILD in clinical practice and cohort enrichment for future clinical trial design. This article has been accepted for publication in 'Annals of the Rheumatic Diseases', 2018 following peer review, and the Version of Record can be accessed online at https://doi.org/10.1136/annrheumdis-2018-213201. Deposited by shareyourpaper.org and openaccessbutton.org. We've taken reasonable steps to ensure this content doesn't violate copyright. However, if you think it does you can request a takedown by emailing help@openaccessbutton.org.
- Published
- 2018
- Full Text
- View/download PDF